Response's proposal to creditors approved:
This article was originally published in Clinica
Response Biomedical has learnt that the British Columbia Supreme Court has approved the company's proposal to its creditors. The approval will trigger the second tranche of a bridge financing, which totals $500,000. The balance of the loan will be paid once the company receives FDA clearance for its RAMP reader and myoglobin assay test. The company went into bankruptcy in September after the FDA rejected its product (see Clinica No 976, p 13). It is believed the rejection prompted some of the Vancouver, British Columbia company's creditors to demand repayment.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.